View Older Stories View More Recent Stories

Mar 20, 2024 08:00AM Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
Mar 13, 2024 07:30AM Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease
Mar 5, 2024 07:30AM Alnylam Pharma (ALNY) Reports Positive KARDIA-2 Topline Study Results When Zilebesiran is Added to Standard of Care Antihypertensives
Mar 5, 2024 07:30AM Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
Feb 27, 2024 08:30AM Alnylam to Webcast Presentations at Upcoming March Investor Conferences
Feb 15, 2024 08:00AM Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity
Jan 29, 2024 08:00AM Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2023 Financial Results
Jan 9, 2024 08:05AM Alnylam CEO Yvonne Greenstreet Named 2024 Woman of the Year by Healthcare Businesswomen’s Association
Jan 8, 2024 05:23AM Alnylam Pharma (ALNY) Reports Prelim Q4 and FY23 Global Net Product Revenues
Jan 7, 2024 06:00PM Alnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional Updates
Jan 2, 2024 07:30AM Alnylam to Webcast Presentation at 42nd Annual J.P. Morgan Healthcare Conference
Dec 13, 2023 07:31AM Alnylam Pharma (ALNY) Highlights Significant Progress with Platform Innovation and Clinical Pipeline
Dec 13, 2023 07:30AM Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day
Dec 6, 2023 08:00AM Alnylam to Webcast Virtual R&D Day
Nov 30, 2023 08:00AM Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2023
Nov 13, 2023 05:33AM Alnylam Pharma (ALNY) Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran
Nov 11, 2023 04:00PM Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High
Nov 7, 2023 08:00AM Alnylam to Webcast Presentations at Upcoming November Investor Conferences
Nov 2, 2023 08:00AM Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity
Oct 26, 2023 02:00PM Alnylam Recognized by Science Magazine as Top Employer for Fifth Consecutive Year
Oct 25, 2023 05:19PM Alnylam Pharma (ALNY) Announces Publication of Results from APOLLO-B Phase 3 Study of Patisiran
Oct 25, 2023 05:19PM Alnylam Announces Publication of Results from APOLLO-B Phase 3 Study of Patisiran in Patients with the Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine
Oct 25, 2023 11:13AM Alnylam Pharma (ALNY) Reports Additional Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Oct 25, 2023 11:05AM Alnylam Reports Additional Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Oct 19, 2023 08:00AM Alnylam to Webcast Conference Call Discussing Third Quarter 2023 Financial Results
Oct 9, 2023 07:30AM Alnylam Pharma (ALNY) Announces Receipt of CRL from U.S. FDA for sNDA for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Oct 9, 2023 07:30AM Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Oct 6, 2023 07:00AM Alnylam to Present Additional Data for Patisiran in Patients With the Cardiomyopathy of ATTR Amyloidosis, Including 24-Month Results From the APOLLO-B Phase 3 Study, at the Heart Failure Society of Am
Sep 13, 2023 04:57PM Alnylam Pharma (ALNY) Reports Positive FDA AdCom Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Sep 13, 2023 04:57PM Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Sep 13, 2023 07:01AM Alnylam (ALNY) Stock Trading Halted Today Ahead FDA Advisory Committee to Review sNDA for Patisiran for Cardiomyopathy of ATTR Amyloidosis
Sep 13, 2023 07:00AM Alnylam Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Sep 7, 2023 07:01AM Alnylam Pharma (ALNY) Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran
Sep 7, 2023 07:00AM Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovas
Aug 3, 2023 08:00AM Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity
Aug 2, 2023 08:30AM Alnylam to Webcast Presentation at Canaccord Genuity 43rd Annual Growth Conference
Jul 24, 2023 01:00AM Alnylam Announces Partnership with Roche to Co-Develop and Co-Commercialize Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension in Patients with High Cardiovascular Risk
Jul 20, 2023 08:00AM Alnylam to Webcast Conference Call Discussing Second Quarter 2023 Financial Results
Jul 19, 2023 05:00PM Alnylam Pharma (ALNY) Announces Publication of Phase 1 Study Results for Zilebesiran
Jul 19, 2023 05:00PM Alnylam Announces Publication of Phase 1 Study Results for Zilebesiran in the New England Journal of Medicine
Jul 17, 2023 05:54AM Alnylam Pharma (ALNY) Reports Updated Positive Interim Phase 1 Results for ALN-APP
Jul 17, 2023 02:21AM Alnylam Reports Updated Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Jun 30, 2023 09:00AM Alnylam Pharma (ALNY) Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Jun 30, 2023 09:00AM Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Jun 5, 2023 04:00PM Alnylam to Webcast Presentation at Goldman Sachs 44th Annual Global Healthcare Conference
May 22, 2023 05:46AM Alnylam Pharma (ALNY) Presents 18-Month Results from the APOLLO-B Phase 3 Study of Patisiran
May 20, 2023 10:50AM Alnylam Presents 18-Month Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
May 4, 2023 08:00AM Alnylam Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Period Activity
May 3, 2023 04:00PM Alnylam to Webcast Presentation at BofA Securities 2023 Health Care Conference
Apr 26, 2023 04:05PM Regeneron (REGN) and Alnylam (ALNY) Report Positive Interim Phase 1 Clinical Data on ALN-APP
View More Recent Stories View Older Stories